News

Upsher-Smith Laboratories launches testosterone gel (1%)

BY Michael Johnsen

MAPLE GROVE, Minn. — Upsher-Smith Laboratories on Wednesday announced the launch of testosterone gel (1%), the generic of Vogelxo (testosterone) gel 1%, for topical use. Newly approved by the Food and Drug Administration, it is the first and only available generic testosterone replacement therapy available in three configurations, the company stated. Testosterone Gel (1%) offers once-daily dosing, 24-hour coverage and three configurations: unit-dose tubes and packets and metered-dose pumps.  
 
Vogelxo and testosterone gel are a prescription medicine that contains testosterone. Vogelxo and testosterone gel are used to treat adult males who have low or no testosterone and those with conditions associated with low or no testosterone.
 
"The generic availability of testosterone gel in three convenient configurations is an important advance in the testosterone replacement therapy marketplace and should greatly increase access for the patients who need it," said Mark Evenstad, president and CEO of Upsher-Smith.
 
According to the American Urological Association, 39% of men older than 45 years of age have low testosterone, but few are being treated.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...
News

Study: Vacationers purchase based on location, not brand

BY Marianne Wilson

DENVER — While on summer vacation, nearby location trumps brands for many types of consumer purchases, and mobile devices will be the dominant form of search.

A new study conducted by location marketing automation provider Placeable shows that proximity is apparently so important that only 1% of vacationers consider reviews when looking to replace a forgotten item.

In addition, 65% of the travelers surveyed report that they seek restaurants and retail locations within five miles of their current location while on vacation. Seventy-six percent reported that they search for local retailers, and 89% look for local restaurants while they are away from home.

Most consumers use mobile devices to find products, services and places while they are away. Placeable reports that more than 85% of consumers search for restaurants and retailers on their mobile device while they are on vacation, and 54% of travelers postpone researching restaurants until they are already on vacation.

“Enterprise brands must optimize themselves locally to capture vacationers searching for non-brand products, services and places,” said Ari Kaufman, CEO of Placeable. “Travelers are increasingly dependent on their mobile devices while on vacation. Based on vacationer preference towards proximity rather than brand, accurate location data and optimized web sites are paramount. Enterprise advertisers must leverage web and mobile locators with local landing pages to capture vacationers that are searching for the closest business.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...
News

Forest Labs closes deal on Furiex Pharmaceuticals for $1.1 billion

BY Michael Johnsen

DUBLIN – Actavis on Wednesday announced that its subsidiary Forest Labs has successfully completed its acquisition of Furiex Pharmaceuticals in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug, following approval.
 
In connection with the close of the Furiex acquisition, Actavis further announced that it has closed the transaction related to the sale of Furiex's royalties on alogliptin and Priligy to Royalty Pharma for approximately $415 million.
 
"The strategic acquisition of Furiex strengthens Actavis' focus on gastroenterology where we are an industry leader, positioning us for continued long-term growth in IBS treatment," said Brent Saunders, CEO and president of Actavis. "Furiex's lead development product eluxadoline is a natural extension to our GI business, complementing our Linzess, Asacol and Delzicol franchises, as well as the products acquired as part of the acquisition of Aptalis earlier this year. If approved, eluxadoline could represent a significant advance in the treatment of IBS-D, and would give Actavis one of the broadest product offerings for the $38 billion GI disease market," he said. "This product, if successful, would make Actavis even more relevant to gastroenterologists and primary care physicians in meeting significant patient needs."
 
Eluxadoline is a first-in-class, locally-acting mu opioid receptor agonist and delta opioid receptor antagonist for treating symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D), a condition that affects approximately 28 million patients in the United States and Europe. In February 2014, Furiex announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of IBS-D met both the Food and Drug Administration and the European Medicines Agency formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.
 
Actavis expects to be in a position to announce an acceptance for filing of the new drug application for eluxadoline by the end of the third quarter of 2014.
 
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...